Intermittent fasting and health.

What the evidence shows

A 2020 systematic review (Welton et al., Canadian Family Physician) of 27 trials enrolling 944 participants reported that every included trial found weight loss — ranging from 0.8% to 13.0% of baseline body weight — with no serious adverse events reported across the studies it examined.

A 2021 umbrella review (Patikorn et al., JAMA Network Open) synthesised existing meta-analyses of randomised controlled trials and found intermittent fasting associated with improvements in body weight, body composition, and several cardiometabolic risk factors. The authors were explicit about the quality of that evidence, however: of the statistically significant beneficial associations they identified, only one — modified alternate-day fasting reducing BMI over one to two months — was supported by high-quality evidence, while the large majority of associations rested on low or very-low-quality evidence.

The widely cited 2019 review by de Cabo and Mattson (New England Journal of Medicine) describes the mechanistic rationale — a "metabolic switch" from glucose to ketone-based fuel during prolonged fasting — and summarises human and animal data suggesting fasting regimens can improve glucose regulation, blood pressure, and markers of inflammation. Earlier reviews by Longo and Mattson (2014) and Anton et al. (2018) frame the same metabolic switch as the plausible common pathway behind these effects.

What's uncertain

Whether fasting beats simple calorie restriction. Much of the measured benefit tracks the weight and energy-intake reduction that fasting produces, and the reviews do not establish that intermittent fasting is superior to continuous calorie restriction for weight loss when total intake is matched. The umbrella review's central caution — that most beneficial findings are low-certainty — applies directly here.

Cardiovascular and long-term outcomes. The American Heart Association's 2017 scientific statement (St-Onge et al., Circulation) reviewed meal timing and frequency and concluded that irregular eating patterns appear less favourable for a healthy cardiometabolic profile, but it stopped short of specific prescriptive recommendations and called for more rigorous research. Hard clinical endpoints — cardiovascular events, mortality — have not been established for intermittent fasting in long-term trials.

Population safety. The trials underpinning these reviews are generally short and enrol healthy or overweight/obese adults. They say little about people who are pregnant, have a history of disordered eating, are insulin-dependent, or are under 18 — groups for whom fasting may carry distinct risks.

Bottom line

The secondary literature supports a measured reading: intermittent fasting is a viable approach to short-term weight loss and produces favourable changes in some metabolic markers, but the evidence for advantages beyond what equivalent calorie restriction would achieve — and for long-term or disease-specific benefit — is currently limited and of mostly low certainty.